Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models

Head and neck squamous cell carcinoma (HNSCC) currently only has one FDA-approved cancer intrinsic targeted therapy, the epidermal growth factor receptor (EGFR) inhibitor cetuximab, to which only approximately 10% of tumors are sensitive. In order to extend therapy options, we subjected patient-deri...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Cancer Biol Ther
المؤلفون الرئيسيون: Ouyang, Xiaoming, Barling, Ashley, Lesch, Aletha, Tyner, Jeffrey W., Choonoo, Gabrielle, Zheng, Christina, Jeng, Sophia, West, Toni M., Clayburgh, Daniel, Courtneidge, Sara A., McWeeney, Shannon K., Kulesz-Martin, Molly
التنسيق: Artigo
اللغة:Inglês
منشور في: Taylor & Francis 2018
الموضوعات:
Research Paper
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6300392/
https://ncbi.nlm.nih.gov/pubmed/29856687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1451285
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة